Sharps Technology Inc (SKYA)

A. Company Overview

Sharps Technology, Inc. is a medical device company specializing in the design and commercialization of innovative safety syringes. Established and incorporated under the laws of Wyoming on December 16, 2017, the company underwent reincorporation as a Nevada corporation on March 22, 2022. This transition was executed through a merger, which was sanctioned by both the board of directors and the holders of a majority of the company’s common stock. The primary aim of Sharps Technology is to develop and market a range of intellectual properties that facilitate the production of smart safety syringes and advanced drug delivery systems. Following the acquisition of relevant intellectual property in late 2017, the company has focused on evolving and commercializing its product lines.

B. Business Operations

Acquisition and Product Development

In June 2020, Sharps Technology entered into an asset and share purchase agreement with Safegard Medical Kft., which was further amended in subsequent months. This agreement provided Sharps with the option to purchase the stock or specific assets of Safegard, which included the Securegard and Sologard product lines and a manufacturing facility located in Hungary. This facility is both FDA- and CE-registered for the production of safety syringes. The completion of this acquisition occurred on July 6, 2022. The product lines acquired are characterized by multi-feature safety syringes that had previously established market acceptance.

The company’s product portfolio comprises smart safety syringes branded as Securgard™, Sologard™, and Sharps Provensa™, which incorporate advanced safety and reuse prevention features aimed at reducing waste during medical procedures. Despite possessing an innovative product lineup focused on meeting pressing healthcare needs, Sharps Technology has yet to generate revenue from sales of these products.

Partnerships and Agreements

To enhance its operational capabilities, Sharps Technology has forged agreements with Nephron Pharmaceuticals Corporation and its affiliates. The NPC agreement includes support for various developmental initiatives and an emphasis on several key areas like manufacturing and distribution. The company's strategy involved creating a Pharma Services Program to discover new business development windows, which is aimed at fulfilling the increasing market demand for next-generation drug delivery systems.

On September 22, 2023, a pivotal Asset Purchase Agreement was established with Nephron, focusing on acquiring specific manufacturing equipment and leasehold improvements necessary for future production. However, this agreement is contingent upon securing adequate financing, emphasizing the financial challenges the company may face in its development trajectory.

C. Product Lines

Disposable Syringes

Sharps Technology’s disposable syringes are designed with ultra-low waste technology, significantly reducing the amount of injectable medication lost during administration. This product line incorporates less than 20 microliters of dead space, contrasting sharply with competitors that may present up to 140 microliters of waste space. The syringes boast both passive and active safety features, effectively addressing three critical concerns within the healthcare sector: accidental needlestick injuries, wasted medications, and the prevention of needle reuse. These syringes are aligned with the World Health Organization’s requirements, further validating their design and functionality.

Prefillable Syringes

The anticipated expansion into prefillable syringe systems signifies another aspect of Sharps Technology's product strategy. This sector is poised for growth, with projected supply activities set to commence in early 2025 as a direct result of the collaborative agreements with Nephron and Roncadelle Operations. These systems are expected to utilize high-quality inert polymer materials that match the durability and stability offered by traditional glass syringes, addressing concerns about leachables and providing compliance with established regulatory standards.

D. Competitive Landscape

Sharps Technology operates within a competitive market landscape featuring established players such as Retractable Technologies, Becton Dickinson & Company, and Medtronic. These competitors are often endowed with greater financial clout and broader sales networks, creating a challenging environment for a company focused on niche markets within the medical device sector. Sharps Technology distinguishes itself by prioritizing healthcare worker safety and product efficacy, alongside its commitment to delivering innovative syringe solutions with reduced waste and enhanced safety features.

E. Regulatory Environment

Operating in the medical device sector necessitates strict adherence to regulatory standards enforced by federal entities. In the United States, this is primarily governed by the Federal Food, Drug, and Cosmetic Act, and enforced by the FDA. Devices must undergo premarket clearance or approval based on their classification, with those considered to pose greater risk requiring more stringent controls. Sharps Technology’s offerings have benefitted from compliance with these regulatory frameworks, crucial to maintaining market access and ensuring safety.

F. Intellectual Property

Intellectual property forms a cornerstone of Sharps Technology’s business strategy, particularly with respect to its patented designs and technologies. The company holds several key patents that protect its innovative safety syringe technology and methods, including designs aimed at reducing waste and enhancing safety during administration. These patents are critical to maintaining competitive advantages over market rivals and are pivotal in facilitating the ongoing development of the company's innovative product pipeline.

G. Workforce

The company operates with a team of 57 full-time employees, including key leadership positions such as the Chief Executive Officer and Chief Financial Officer. The majority of the workforce is located at facilities in Hungary, essential for the production operations. As production demands are anticipated to grow, Sharps Technology is likely to scale its workforce to support larger operational capacities.